Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFenner PLC Regulatory News (FENR)

  • There is currently no data for FENR

Acquisition

2 Feb 2015 07:00

RNS Number : 6949D
Fenner PLC
02 February 2015
 

02 February 2015

Fenner PLC ("Fenner")

Acquisition of Charter Medical Limited ("Charter")

Fenner is pleased to announce that its wholly owned subsidiary Fenner Drives, Inc. has acquired 100% of the share capital of Charter from its parent company Lydall, Inc. a publicly traded company (NYSE: LDL) headquartered in Connecticut. Charter will be integrated into Solesis Medical Technologies ("Solesis"), part of Fenner's AEP division.

The consideration of US$29.9m was satisfied in cash at completion and the transaction is expected to be earnings enhancing immediately upon acquisition.

Charter manufactures specialty single-use assemblies and Class I and Class II medical devices for the collection, processing, storage and filtration of biological and bioprocessing fluids. Charter also produces bio-containers and fluid management sets that serve a range of life science applications including biopharmaceutical manufacturing, cell therapy and cryogenic storage. Charter is a single site company based in Winston-Salem, North Carolina.

As at 31 December 2014, unaudited gross assets acquired were US$6.9m with underlying EBITDA (1) of US$3.3m for the 12 months to 31 December 2014 on sales of US$19.6m. 

The entire workforce of Charter have become employees of Fenner upon completion and will continue to be led by General Manager, Mr. Gael Peron.

Nick Hobson, CEO of Fenner PLC, commented:

"In common with all businesses in our AEP division, Charter applies its polymer technology to solving problems in performance-critical applications. Charter has a strong, established business in blood transfusion and filtration markets and has exciting opportunities in the bio-processing and regenerative medicine markets, in which Fenner is already active and which are experiencing rapid growth. 

The acquisition of Charter, which will provide an attractive addition to the capabilities and offerings of Solesis, continues Fenner's strategy to develop our medical business both organically and by acquisition."

For further information please contact:

 

Fenner PLC 01482 626501

Nick Hobson, Chief Executive

John Pratt, Finance Director

 

Weber Shandwick Financial 020 7067 0700

Nick Oborne / Tom Jenkins

 

 

(1) Adjusted for historic non-recurring items

 

Notes to editors:

 

Fenner PLC is a world leader in reinforced polymer technology, providing local engineered solutions for performance-critical applications. The Group operates through two divisions:

Engineered Conveyor Solutions: the ECS division, trading under the Fenner Dunlop, Fenner and Dunlop brand names, is a recognised leader in the global conveying market. The division offers a unique, comprehensive suite of products and services, which serve the conveying needs of mining, power generation and bulk handling markets.

Advanced Engineered Products: the AEP division uses advanced polymeric materials and technical expertise to provide high value-added solutions to customers' most challenging engineering problems. Customers are spread across a variety of end-user segments, including oil & gas and medical which account for some 40 per cent of divisional revenue, together with construction, transportation, automation and general industrial. AEP's trading names are recognised globally and include CDI Energy Products, EGC Critical Components, Hallite, AIP Precision Machining, Fenner Precision, Fenner Drives, James Dawson, Mandals, Secant Medical and Xeridiem.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ACQUARWRVBAURAR
Date   Source Headline
28th Oct 20154:16 pmRNSHolding(s) in Company
22nd Oct 20159:41 amRNSHolding(s) in Company
19th Oct 20152:36 pmRNSHolding(s) in Company
7th Oct 20159:20 amRNSHolding(s) in Company
10th Sep 20153:34 pmRNSHolding(s) in Company
10th Sep 201511:49 amRNSHolding(s) in Company - Amendment
9th Sep 20154:02 pmRNSHolding(s) in Company
9th Sep 20151:24 pmRNSHolding(s) in Company
8th Sep 20157:00 amRNSPre-Close Trading Statement
4th Sep 20153:06 pmRNSHolding(s) in Company
2nd Sep 20151:13 pmRNSHolding(s) in Company
2nd Sep 20159:34 amRNSBlocklisting Interim Review
24th Jul 201511:11 amRNSHolding(s) in Company
22nd Jul 20157:00 amRNSTrading Update
6th Jul 201510:16 amRNSHolding(s) in Company
17th Jun 20154:39 pmRNSHolding(s) in Company
28th Apr 201511:09 amRNSHolding(s) in Company
22nd Apr 20157:00 amRNSHalf Yearly Report
20th Apr 20153:53 pmRNSHolding(s) in Company
10th Apr 20152:21 pmRNSHolding(s) in Company
8th Apr 20152:37 pmRNSHolding(s) in Company
2nd Apr 20159:37 amRNSHolding(s) in Company
25th Mar 20154:07 pmRNSHolding(s) in Company
20th Mar 20158:46 amRNSHolding(s) in Company
19th Mar 20151:31 pmRNSHolding(s) in Company
12th Mar 20157:00 amRNSPre-Close Trading Statement
2nd Mar 201511:23 amRNSBlocklisting Interim Review
2nd Feb 20157:00 amRNSAcquisition
30th Jan 20153:54 pmRNSDirector/PDMR Shareholding
29th Jan 20151:24 pmRNSDirector/PDMR Shareholding
21st Jan 201511:10 amRNSDirectorate Change
21st Jan 201511:08 amRNSDirector Declaration
15th Jan 201512:09 pmRNSResult of AGM
14th Jan 20157:00 amRNSAGM Trading Update
1st Dec 201411:44 amRNSDirector/PDMR Shareholding
21st Nov 20141:03 pmRNSDirector/PDMR Shareholding
21st Nov 201411:36 amRNSDirector/PDMR Shareholding
21st Nov 201411:27 amRNSDirector/PDMR Shareholding
20th Nov 20143:34 pmRNSDirector/PDMR Shareholding
18th Nov 201410:46 amRNSDirector/PDMR Shareholding
12th Nov 201410:01 amRNSDirector/PDMR Shareholding
11th Nov 20147:00 amRNSFinal Results
6th Nov 201410:03 amRNSHolding(s) in Company
5th Nov 20142:38 pmRNSHolding(s) in Company
23rd Sep 20149:26 amRNSHolding(s) in Company
9th Sep 20147:00 amRNSPre-Close Trading Statement
2nd Sep 20144:04 pmRNSTotal Voting Rights
2nd Sep 20142:57 pmRNSDirector/PDMR Shareholding
2nd Sep 20142:44 pmRNSBlocklisting Interim Review
27th Aug 20149:38 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.